A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Launched by HOFFMANN-LA ROCHE · Dec 3, 2015
Trial Information
Current as of May 08, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with a non-myeloid malignancy
- • Anemia
- Exclusion Criteria:
- • Transfusion of red blood cells within 2 months of study drug
- • Treatment-resistant hypertension
- • Acute or chronic bleeding (requiring therapy) within 3 months of study drug
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Caracas, , Venezuela
Valencia, , Venezuela
Patients applied
Trial Officials
Clinical Trials
Study Chair
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials